a public good project by the
Synthesis
Company
of California

© 2026

Lars Johannesen | doi.page

0 works0 citations0 h-index

Lars Johannesen

United States Food and Drug Administration(US)Center for Drug Evaluation and Research(US)

Publications by Year

Research Areas

Cardiac electrophysiology and arrhythmias, ECG Monitoring and Analysis, Ion channel regulation and function, Cardiac pacing and defibrillation studies, Receptor Mechanisms and Signaling

Most-Cited Works

→ An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel(2016)288 cited
→ Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias(2016)272 cited
→ Differentiating Drug-Induced Multichannel Block on the Electrocardiogram: Randomized Study of Dofetilide, Quinidine, Ranolazine, and Verapamil(2014)257 cited
→ Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase(2015)177 cited
→ Late sodium current block for drug‐induced long QT syndrome: Results from a prospective clinical trial(2015)142 cited
→ Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study(2017)129 cited

→ Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil(2015)

126 cited

→ Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk(2017)123 cited

→ The IQ‐CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”(2013)99 cited

→ Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study(2018)91 cited